Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) surged 15% after receiving a key regulatory boost from the U.S. Food and Drug ...

Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is one of the best low priced pharma stocks to buy now. On June 30, Rocket ...

Rocket Pharma receives US FDA regenerative medicine advanced therapy designation for RP-A601 gene therapy: Cranbury, New Jersey Saturday, July 19, 2025, 15:00 Hrs [IST] Rocket Pha ...

Rocket Pharmaceuticals received a regenerative medicine advanced therapy designation from the Food and Drug Administration for its heart disease treatment.

Rocket Pharmaceuticals is acquiring Renovacor, a gene therapies developer whose lead program addresses a particular genetic mutation that leads to a type of heart failure. The all-stock deal gives ...

COO and President of Rocket Pharmaceuticals, Kinnari Patel’s, shares how the company is using gene therapy to eradicate diseases in children.

Image: Courtesy of Rocket Pharma. RCKT Rocket Pharmaceuticals Inc. $2.80-0.36 % Stock Score Locked: Edge Members Only. Benzinga Rankings give you vital metrics on any stock – anytime.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is advancing an integrated and sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders.

Rocket Pharmaceuticals is reviving the gene therapy market with promising early efficacy results. Find out if RCKT stock can rebound to $50 levels.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders.

Rocket Pharmaceuticals RP-A501 Phase II Trial Design (Rocket Pharmaceuticals) While three ex-vivo therapies in Rocket's pipeline show promise, RP-A501 appears to be the leading asset.